RNA therapeutics are now a clinical reality
Interviewee/Contributor
Tara Raveendran
Organisation
Shore Capital
Research Directory
Genmab looks ahead to next phase of growth
Interviewee/ContributorJan van de WinkelOrganisationGenmab A/SThe oncology drug success rate is improving
Interviewee/ContributorBruno PagliaraOrganisationOn-kòs Pharma ConsultingAfter probing the unknown, BerGenBio finds a gem
Interviewee/ContributorRichard GodfreyOrganisationBerGenBio ASAEuropean biotechs pause during Q3
Interviewee/ContributorWilliam EllingtonOrganisationMedNousHow basket trials are changing cancer research
Interviewee/ContributorShiva MemariOrganisationVertical KnowingBattle looms over immunotherapy combination
Interviewee/ContributorRobin DavisonOrganisationNew Science Global Healthcare FundAltheia Science Srl: Italian biotech raises $11 mln for autoimmunity
Interviewee/ContributorMedNous financing articleOrganisationAltheia Science SrlWill CRISPR be safe enough for the clinic?
Interviewee/ContributorJonathan MooreTargeting the genetic background of cancers
Interviewee/ContributorNiall Martin and Jonathan TobinOrganisationArtios Pharma Ltd